pSivida Corp (PSDV)

3.23
0.06 1.89
NASDAQ : Health Care
Prev Close 3.17
Open 3.12
Day Low/High 3.11 / 3.27
52 Wk Low/High 2.37 / 5.81
Volume 135.77K
Avg Volume 74.60K
Exchange NASDAQ
Shares Outstanding 34.18M
Market Cap 110.05M
EPS 0.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

PSivida Announces 13 New Patents Issued Or Allowed

PSivida Announces 13 New Patents Issued Or Allowed

U.S. and foreign patents for bioerodible Medidur™, new smaller needle Medidur injector and Tethadur™

Primary Endpoint Met In PSivida's Utilization Study Of New Medidur™ Inserter With Smaller Diameter Needle

Primary Endpoint Met In PSivida's Utilization Study Of New Medidur™ Inserter With Smaller Diameter Needle

Results to Form Part of Planned Applications for Marketing Approvals in EU and US

PSivida Names Dario Paggiarino, M.D. As Chief Medical Officer

PSivida Names Dario Paggiarino, M.D. As Chief Medical Officer

Industry Veteran Brings Over 25 Years of Pharmaceutical and Drug Development Experience

PSivida's Medidur™ Maintains Same High Statistical Significance In Primary Endpoint Through 12 Months In First Phase 3 Trial (p Less Than 0.00000001)

PSivida's Medidur™ Maintains Same High Statistical Significance In Primary Endpoint Through 12 Months In First Phase 3 Trial (p Less Than 0.00000001)

Incremental Risk of Elevated IOP Relative to Control Decreases Through Last Follow-up Visit

Data Shows PSivida's Tethadur™ Provides Prolonged, Sustained Release Of Avastin® With High Drug Efficacy

Data Shows PSivida's Tethadur™ Provides Prolonged, Sustained Release Of Avastin® With High Drug Efficacy

Data Presented at 2016 Annual Meeting & Exposition of the Controlled Release Society

PSivida Corp. Announces Plan To Consolidate All Research And Development In Current U.S. Facility

PSivida Corp. Announces Plan To Consolidate All Research And Development In Current U.S. Facility

Plan to Facilitate Product Development and Reduce Operating Expenses

Investigator-Sponsored Phase 2 Study Results Show PSivida's Medidur® Fully Controlled Uveitis For Two Years With No Recurrence Of Disease While Visual Acuity Continued To Improve

Investigator-Sponsored Phase 2 Study Results Show PSivida's Medidur® Fully Controlled Uveitis For Two Years With No Recurrence Of Disease While Visual Acuity Continued To Improve

Study Results Showing No Recurrence of Disease and Statistically Significant Improvement in Visual Acuity to be Published in Ophthalmology

PSivida Closes $17.8 Million Offering

PSivida Closes $17.8 Million Offering

Today's Weak On High Volume Stock: PSivida (PSDV)

Today's Weak On High Volume Stock: PSivida (PSDV)

Trade-Ideas LLC identified pSivida (PSDV) as a weak on high relative volume candidate